Auris Health raises another $220M to commercialize its robotic surgery platform

Formerly known as Auris Surgical Robotics, the Fierce 15 winner received FDA approval in lung cancer patients in March. (Auris Health)

Robotic surgery platform developer Auris Health has raked in another $220 million in equity financing, bringing its fundraising total to more than $700 million.

The new money will be used to help the 2016 Fierce 15 winner transition to a commercial-stage company following the FDA approval of its Monarch endoscopic platform this past spring, as well as to fund the development of new robotic interventions.

“We are pleased with our progress in launching the Monarch platform, which was initiated earlier this year,” said Auris founder and CEO Frederic Moll, M.D., who previously co-founded Intuitive Surgical.


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

RELATED: FierceMedicalDevices' 2016 Fierce 15 | Auris Surgical Robotics

“This funding will enable us to expand our commercialization efforts for endobronchial applications, and will also support our mission to pioneer the next era of medical intervention across a broader spectrum of procedures,” Moll said.

The round was led by Partner Fund Management with participation from the company’s previous investors Mithril Capital, Lux Capital and Viking Global Investors. Wellington Management, D1 Capital Partners and Senator Investment Group also joined as new backers.

RELATED: 2018 could see a robotic surgery shake-up

Formerly known as Auris Surgical Robotics, the Redwood City, California-based company received FDA approval for diagnostic and therapeutic bronchoscopic procedures in lung cancer patients, using a flexible robotic endoscope to treat small and hard-to-reach nodules in the periphery of the lung.

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.